Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients
Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients
(2025)
Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients
Psoriasisisachronicimmune-mediated inflammatory skin
disorder, frequently associated with comorbidities such as obesity, which can
exacerbate its severity and hinder treatment efficacy. Psoriasis pathogenesis
involves complex interactions among genetic, environmental, hormonal
factors, and is characterized by dysregulated immune responses. In this study,
we investigated the relationship between obesity and psoriasis, exploring the
impact of circulating levels of adipokines on disease severity, comorbidities, and
treatment response to anti-IL-17 and anti-IL-23 biologics.
Id prodotto:
146742
Handle IRIS:
11562/1167109
ultima modifica:
23 luglio 2025
Citazione bibliografica:
Belli, Roberta; Dattolo, Anna; Sampogna, Francesca; Gubinelli, Emanuela; Lulli, Daniela; Moretta, Gaia; Scala, Emanuele; Sanna, Luca; Megna, Matteo; Vittoria Cannizzaro, Maria; Parisi, Melania; Luordi, Cecilia; Scarponi, Claudia; Quaranta, Maria; Grazia Lolli, Maria; Silvestri, Lorena; Gisondi, Paolo; Girolomoni, Giampiero; Pallotta, Sabatino; Albanesi, Cristina; Mercurio, Laura; Madonna, Stefania,
Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients«FRONTIERS IN IMMUNOLOGY»
, 2025
, pp. 1-20